Cardiovascular effects of pipecuronium and pancuronium in patients undergoing coronary artery bypass grafting.
Tassonyi
E
E
Department of Anesthesiology, University Hospital, Geneva, Switzerland.
Neidhart
P
P
Pittet
J F
JF
Morel
D R
DR
Gemperle
M
M
D000368:Aged; D015113:Androstane-3,17-diol / Q000009:adverse effects* / Q000031:analogs & derivatives; D000732:Androstanols / Q000009:adverse effects*; D001919:Bradycardia / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D008875:Middle Aged; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects*; D010197:Pancuronium / Q000009:adverse effects*; D017300:Pipecuronium; D010879:Piperazines / Q000009:adverse effects*; D011897:Random Allocation
D000732:Androstanols; D009466:Neuromuscular Blocking Agents; D010879:Piperazines; D017300:Pipecuronium; D015113:Androstane-3,17-diol; D010197:Pancuronium